NDC product
Plavix
NDC 0024-1171 · Sanofi-Aventis U.S. LLC
Key facts
| Product NDC | 0024-1171 |
|---|---|
| Proprietary name | Plavix |
| Nonproprietary name | clopidogrel |
| Substances | CLOPIDOGREL BISULFATE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Sanofi-Aventis U.S. LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA020839 |
| Pharmacologic classes | Cytochrome P450 2C8 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA] |
| Marketing start | Nov 17, 1997 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: